Jenn‐Yu Wu

1.5k total citations
18 papers, 1.2k citations indexed

About

Jenn‐Yu Wu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jenn‐Yu Wu has authored 18 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 2 papers in Surgery. Recurrent topics in Jenn‐Yu Wu's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (10 papers). Jenn‐Yu Wu is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (11 papers) and Lung Cancer Research Studies (10 papers). Jenn‐Yu Wu collaborates with scholars based in Taiwan. Jenn‐Yu Wu's co-authors include Jin‐Yuan Shih, Chong‐Jen Yu, Pan‐Chyr Yang, James Chih‐Hsin Yang, Yeun‐Chung Chang, Shang‐Gin Wu, Yih‐Leong Chang, Chien‐Hung Gow, Y. L. Hsu and Chao‐Chi Ho and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, Clinical Cancer Research and International Journal of Cancer.

In The Last Decade

Jenn‐Yu Wu

18 papers receiving 1.1k citations

Peers

Jenn‐Yu Wu

PRM

ONCOL

SURGE

Rachael Lawrance United States

Marcelo V. Negrão United States

Hiroshi Wakui Japan

Antonio Pazzola Italy

D. Kanaloupiti Greece

Seisuke Nagase Japan

Sakiko Otani Japan

M. Harada Japan

Shinsuke Saisho Japan

Robert S. de Jong Netherlands

Rachael Lawrance United States

Jenn‐Yu Wu

729 ×0.7

PRM

394 ×0.5

ONCOL

191 ×0.6

460 ×1.9

61 ×1.1

SURGE

Citations per year, relative to Jenn‐Yu Wu Jenn‐Yu Wu (= 1×) peers Rachael Lawrance

Countries citing papers authored by Jenn‐Yu Wu

Since Specialization

Citations

This map shows the geographic impact of Jenn‐Yu Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenn‐Yu Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenn‐Yu Wu more than expected).

Fields of papers citing papers by Jenn‐Yu Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenn‐Yu Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenn‐Yu Wu. The network helps show where Jenn‐Yu Wu may publish in the future.

Co-authorship network of co-authors of Jenn‐Yu Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Jenn‐Yu Wu. A scholar is included among the top collaborators of Jenn‐Yu Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenn‐Yu Wu. Jenn‐Yu Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wu, Jenn‐Yu, Chong‐Jen Yu, & Jin‐Yuan Shih. (2019). Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. 20(6). e620–e630. 44 indexed citations

Yeh, Hung‐Chieh, I‐Wen Ting, Ching-Wei Tsai, Jenn‐Yu Wu, & Chin‐Chi Kuo. (2017). Serum lactate level and mortality in metformin-associated lactic acidosis requiring renal replacement therapy: a systematic review of case reports and case series. BMC Nephrology. 18(1). 229–229. 37 indexed citations

Wu, Jenn‐Yu & Jin‐Yuan Shih. (2016). Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. OncoTargets and Therapy. Volume 9. 6137–6145. 33 indexed citations

Chung, Kuei‐Pin, Shang‐Gin Wu, Jenn‐Yu Wu, et al.. (2012). Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR. Clinical Cancer Research. 18(12). 3470–3477. 54 indexed citations

Wu, Shang‐Gin, Fu‐Chang Hu, Yih‐Leong Chang, et al.. (2012). FrequentEGFRmutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. European Respiratory Journal. 41(2). 417–424. 37 indexed citations

Wu, Jenn‐Yu, Chong‐Jen Yu, Yeun‐Chung Chang, et al.. (2011). Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer. Clinical Cancer Research. 17(11). 3812–3821. 361 indexed citations

Wu, Jenn‐Yu, Jin‐Yuan Shih, Kuan‐Yu Chen, et al.. (2011). Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations. Medicine. 90(3). 159–167. 24 indexed citations

Wu, Jenn‐Yu, Shang‐Gin Wu, James Chih‐Hsin Yang, et al.. (2010). Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer. 72(2). 205–212. 63 indexed citations

Wu, Jenn‐Yu, James Chih‐Hsin Yang, Y. L. Hsu, et al.. (2010). Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 11(4). 257–263. 6 indexed citations

10.

Wu, Jenn‐Yu, Chong‐Jen Yu, Jin‐Yuan Shih, James Chih‐Hsin Yang, & Pan‐Chyr Yang. (2009). Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer. 67(3). 348–354. 18 indexed citations

11.

Wu, Jenn‐Yu, Hsin-Yi Chen, Chin‐Chung Shu, & Chong‐Jen Yu. (2009). Kommerell diverticulum, right-sided aorta, and left aberrant subclavian artery in a patient with dysphagia. Journal of Thoracic and Cardiovascular Surgery. 139(5). e97–e98. 8 indexed citations

12.

Wu, Jenn‐Yu, Shang‐Gin Wu, Hsin‐Yun Sun, Ping‐Hung Kuo, & Pan‐Chyr Yang. (2009). Critical illness polyneuromyopathy in a patient with disseminated cryptococcal infection. Journal of Hospital Medicine. 4(2). E3–6. 1 indexed citations

13.

Wu, Jenn‐Yu, Jin‐Yuan Shih, James Chih‐Hsin Yang, et al.. (2009). Second‐line treatments after first‐line gefitinib therapy in advanced nonsmall cell lung cancer. International Journal of Cancer. 126(1). 247–255. 49 indexed citations

14.

Wu, Jenn‐Yu, Chong‐Jen Yu, James Chih‐Hsin Yang, et al.. (2008). First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 178(8). 847–853. 60 indexed citations

15.

Wu, Jenn‐Yu, Szu-Chun Hsu, Shih‐Chi Ku, et al.. (2008). Adrenal insufficiency in prolonged critical illness. Critical Care. 12(3). R65–R65. 22 indexed citations

16.

Wu, Jenn‐Yu, Ping‐Hung Kuo, Pi‐Chuan Fan, et al.. (2008). The Role of Non-invasive Ventilation and Factors Predicting Extubation Outcome in Myasthenic Crisis. Neurocritical Care. 10(1). 35–42. 36 indexed citations

17.

Wu, Jenn‐Yu, Shang‐Gin Wu, James Chih‐Hsin Yang, et al.. (2008). Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research. 14(15). 4877–4882. 250 indexed citations

18.

Wu, Shang‐Gin, Yih‐Leong Chang, Y. L. Hsu, et al.. (2008). Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern. The Oncologist. 13(12). 1276–1284. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact